Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed (INSM) has granted inducement awards to 18 new employees as approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4). The awards, issued on March 7, 2025, consist of options to purchase 47,960 shares of Insmed common stock at an exercise price of $74.89 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The stock options come with a 10-year term and feature a four-year vesting schedule. The vesting terms include 25% of shares vesting on the first anniversary, followed by 12.5% vesting every six months through the fourth anniversary, contingent on continued employment.
Insmed (INSM) ha concesso premi di incentivazione a 18 nuovi dipendenti come approvato dal Comitato per la Compensazione dell'azienda secondo la Regola di Quotazione NASDAQ 5635(c)(4). I premi, emessi il 7 marzo 2025, consistono in opzioni per l'acquisto di 47.960 azioni di azioni ordinarie di Insmed a un prezzo di esercizio di $74,89 per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Select Market alla data di concessione.
Le opzioni su azioni hanno un termine di 10 anni e presentano un programma di maturazione di quattro anni. I termini di maturazione prevedono che il 25% delle azioni matura al primo anniversario, seguito dal 12,5% che matura ogni sei mesi fino al quarto anniversario, a condizione di continuare a essere impiegati.
Insmed (INSM) ha otorgado premios de incentivo a 18 nuevos empleados según lo aprobado por el Comité de Compensación de la empresa bajo la Regla de Cotización de NASDAQ 5635(c)(4). Los premios, emitidos el 7 de marzo de 2025, consisten en opciones para comprar 47,960 acciones de acciones comunes de Insmed a un precio de ejercicio de $74.89 por acción, coincidiendo con el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión.
Las opciones sobre acciones tienen un plazo de 10 años y cuentan con un programa de adquisición de cuatro años. Los términos de adquisición incluyen que el 25% de las acciones se adquiere en el primer aniversario, seguido por el 12.5% que se adquiere cada seis meses hasta el cuarto aniversario, condicionado a la continuidad del empleo.
Insmed (INSM)는 18명의 신규 직원에게 NASDAQ 상장 규칙 5635(c)(4)에 따라 보상 위원회에서 승인한 유인 보상을 부여했습니다. 이 보상은 2025년 3월 7일에 발급되었으며, 47,960주의 Insmed 보통주를 $74.89의 행사 가격으로 구매할 수 있는 옵션으로 구성되어 있으며, 이는 부여일의 Nasdaq Global Select Market에서의 종가와 일치합니다.
주식 옵션은 10년의 기간을 가지고 있으며 4년의 취득 일정을 특징으로 합니다. 취득 조건에는 첫 번째 기념일에 25%의 주식이 취득되고, 이후 4년 기념일까지 매 6개월마다 12.5%의 주식이 취득되는 조건이 포함되어 있으며, 이는 계속 고용되는 경우에 한합니다.
Insmed (INSM) a accordé des primes d'incitation à 18 nouveaux employés, comme approuvé par le Comité de rémunération de l'entreprise selon la règle de cotation NASDAQ 5635(c)(4). Les primes, émises le 7 mars 2025, consistent en des options d'achat de 47 960 actions ordinaires d'Insmed à un prix d'exercice de 74,89 $ par action, correspondant au prix de clôture sur le Nasdaq Global Select Market à la date de l'octroi.
Les options d'achat d'actions ont une durée de 10 ans et présentent un calendrier d'acquisition de quatre ans. Les conditions d'acquisition incluent 25 % des actions acquises lors du premier anniversaire, suivies de 12,5 % acquises tous les six mois jusqu'au quatrième anniversaire, sous réserve d'un emploi continu.
Insmed (INSM) hat 18 neuen Mitarbeitern Anreizprämien gewährt, die vom Vergütungsausschuss des Unternehmens gemäß der NASDAQ-Listing-Regel 5635(c)(4) genehmigt wurden. Die Prämien, die am 7. März 2025 ausgegeben wurden, bestehen aus Optionen zum Kauf von 47.960 Aktien der Stammaktien von Insmed zu einem Ausübungspreis von $74,89 pro Aktie, was dem Schlusskurs am Nasdaq Global Select Market am Tag der Gewährung entspricht.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und beinhalten einen vierjährigen Vesting-Zeitplan. Die Vesting-Bedingungen umfassen, dass 25% der Aktien am ersten Jahrestag vesten, gefolgt von 12,5%, die alle sechs Monate bis zum vierten Jahrestag vesten, vorbehaltlich einer fortdauernden Beschäftigung.
- Stock price at $74.89 indicates strong market valuation
- Company expanding workforce with 18 new hires
- Long-term retention incentives through 4-year vesting schedule
- Potential dilution from 47,960 new shares
- Additional compensation expenses from stock options
In connection with the commencement of their employment, the employees received options on March 7, 2025 to purchase an aggregate 47,960 shares of Insmed common stock at an exercise price of
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in
Headquartered in Bridgewater,
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(848) 360-1281
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302396205.html
SOURCE Insmed Incorporated
FAQ
What is the exercise price for INSM's March 2025 inducement stock options?
How many shares were granted in INSM's March 2025 inducement awards?
What is the vesting schedule for INSM's March 2025 inducement options?
When do INSM's March 2025 inducement stock options expire?
